|
Getting your Trinity Audio player ready...
|
September 14, 2026 In drug development, identifying a dangerous compound is only half the challenge. The other is avoiding the premature elimination of a potentially valuable medicine. VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting both problems with its NAMkind™ 3D human tissue models and predictive toxicology platform.
VivoSim has reported that its NAMkind™ Liver platform achieved approximately 91% overall predictive accuracy, 90% sensitivity and 95% specificity against clinical drug-induced liver injury outcomes across a 92-compound small-molecule dataset.
For pharmaceutical companies, the 90%/95% split may be more important than the 91% headline accuracy. Sensitivity measures how effectively the model identifies toxic drugs, while specificity measures how effectively it clears non-toxic drugs. In practical terms, VivoSim’s reported results suggest NAMkind™ may help catch dangerous compounds while reducing the risk of unnecessarily eliminating safer candidates.
Alongside VivoSim Labs, Inc. (NASDAQ: VIVS), investors are also watching Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Volato Group, Inc. (NYSE: SOAR), VS MEDIA Holdings Limited (NASDAQ: VSME) and The Hain Celestial Group, Inc. (NASDAQ: HAIN), which are among stocks moving in early trading.
That distinction can directly affect pharmaceutical capital allocation. A false negative can allow a toxic candidate to consume years and substantial development capital before failing, while a false positive can eliminate a potentially valuable medicine before it has the opportunity to advance.
According to a third-party analyst report from Intro-Act in partnership with PartnerCap Securities, VivoSim’s liver model generated stronger toxicity signals for troglitazone and trovafloxacin, drugs associated with serious liver safety concerns, while showing substantially lower toxicity for the related drugs pioglitazone and levofloxacin, which have different clinical safety profiles. See Complete Research Report
The commercial question is therefore larger than simply detecting toxicity: Can VivoSim help pharmaceutical companies determine which candidates should advance, which should be optimized and which should be stopped before substantially more development capital is committed?
VivoSim is also expanding beyond liver toxicity. Its VitroSense™ AI platform has separately reported up to 96% accuracy predicting drug-induced diarrhea using data from the company’s human intestinal models, while its work involving antibody-drug conjugates (ADCs) could further broaden applications for its human-relevant predictive toxicology technology.
Adding credibility to VivoSim’s broader drug-development history, the company recently received a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) following first-patient dosing in a Phase 2 study involving a drug program previously developed by VivoSim and sold to Lilly. VivoSim remains eligible for up to an additional $45 million in potential regulatory and commercial milestones, although Lilly controls development of the program.
For investors watching VIVS, broader validation and pharmaceutical adoption remain key. If NAMkind™ can maintain its reported sensitivity/specificity balance across larger datasets and additional drug classes, VivoSim could potentially become part of the decision layer between drug discovery and human clinical trials—helping pharmaceutical companies catch dangerous drugs without unnecessarily sacrificing promising ones.
About VivoSim Labs
VivoSim Labs, Inc. (NASDAQ: VIVS) is a biotechnology and CRO services company developing human-relevant predictive toxicology solutions using its NAMkind™ 3D human liver and intestinal tissue models and VitroSense™ AI platform. NAMkind™ Liver demonstrated approximately 91% predictive accuracy, 90% sensitivity and 95% specificity across a 92-compound dataset, while VitroSense™ separately reported up to 96% accuracy predicting drug-induced diarrhea. With broader validation and pharmaceutical adoption, VivoSim’s technology could help drug developers identify toxicity earlier and determine which candidates should advance, be optimized before costly human clinical trials.
About The Street Reports
The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.